Pacer Advisors Inc. Decreases Holdings in Theravance Biopharma, Inc. $TBPH

Pacer Advisors Inc. trimmed its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 13.5% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 293,192 shares of the biopharmaceutical company’s stock after selling 45,766 shares during the quarter. Pacer Advisors Inc. owned 0.57% of Theravance Biopharma worth $4,759,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. lifted its stake in Theravance Biopharma by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 515 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Theravance Biopharma by 18.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 781 shares during the period. Creative Planning lifted its stake in shares of Theravance Biopharma by 6.7% in the 3rd quarter. Creative Planning now owns 13,450 shares of the biopharmaceutical company’s stock valued at $196,000 after acquiring an additional 842 shares during the last quarter. State of Wyoming boosted its holdings in Theravance Biopharma by 5.7% during the 2nd quarter. State of Wyoming now owns 18,928 shares of the biopharmaceutical company’s stock valued at $209,000 after acquiring an additional 1,019 shares during the period. Finally, The Manufacturers Life Insurance Company grew its position in Theravance Biopharma by 6.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,747 shares of the biopharmaceutical company’s stock worth $174,000 after acquiring an additional 1,020 shares during the last quarter. Institutional investors own 99.10% of the company’s stock.

Insider Activity

In related news, major shareholder Eli Samaha sold 273,871 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $17.23, for a total transaction of $4,718,797.33. Following the completion of the sale, the insider owned 9,237,279 shares of the company’s stock, valued at $159,158,317.17. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Rhonda Farnum sold 13,314 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $16.39, for a total value of $218,216.46. Following the sale, the senior vice president owned 232,457 shares in the company, valued at approximately $3,809,970.23. This represents a 5.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 350,011 shares of company stock valued at $6,008,309. 7.65% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on TBPH shares. Weiss Ratings upgraded shares of Theravance Biopharma from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday. Zacks Research downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 8th. Wall Street Zen downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. BTIG Research lowered Theravance Biopharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 29th. Finally, JonesTrading lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Monday, June 29th. Eight research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $19.40.

Theravance Biopharma Trading Up 0.1%

Shares of TBPH stock opened at $16.90 on Thursday. The company’s fifty day moving average price is $16.74 and its 200-day moving average price is $16.95. The stock has a market cap of $871.19 million, a PE ratio of 7.68 and a beta of 0.19. Theravance Biopharma, Inc. has a 12 month low of $11.05 and a 12 month high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) EPS for the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%.The business had revenue of $17.70 million for the quarter. On average, sell-side analysts forecast that Theravance Biopharma, Inc. will post 1.54 earnings per share for the current fiscal year.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.